Compare KW & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KW | RLAY |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1992 | 2020 |
| Metric | KW | RLAY |
|---|---|---|
| Price | $9.84 | $7.48 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $11.00 | ★ $16.00 |
| AVG Volume (30 Days) | 712.1K | ★ 2.0M |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $550,500,000.00 | $8,355,000.00 |
| Revenue This Year | N/A | $19.96 |
| Revenue Next Year | $158.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.93 | N/A |
| 52 Week Low | $5.98 | $1.78 |
| 52 Week High | $10.11 | $9.04 |
| Indicator | KW | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 44.44 |
| Support Level | $9.71 | $7.36 |
| Resistance Level | $10.09 | $7.91 |
| Average True Range (ATR) | 0.18 | 0.46 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 51.00 | 32.42 |
Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).